Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Diagnostics Raises $40.4M in Public Offering

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said yesterday that it has completed its previously announced underwritten public offering.

The company sold approximately 13.9 million shares of its common stock at a price to the public of $2.90 per share, including about 1.8 million shares pursuant to the exercise in full of the underwriters' option to purchase additional shares.

The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting underwriting discounts and commissions and offering expenses.

The company said it anticipates using net proceeds for working capital and general corporate purposes, which may include capital expenditures and research and development, sales and marketing, and general and administrative expenses.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.